Serum IgG Antibody Response to the Protective Antigen (PA) of Bacillus Anthracis Induced by Anthrax Vaccine Adsorbed (AVA) Among U.S. Military Personnel

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2008 Jan 22

PMID 18206278

Citations 11

Authors

Darrell E Singer

Rachel Schneerson

Christian T Bautista

Mark V Rubertone

John B Robbins

David N Taylor

Affiliations

Soon will be listed here.

Abstract

The seroconversion rates and geometric mean concentrations (GMC) of IgG anti-PA for stored sera from U.S. military personnel immunized 3, 4, and 6 times with the U.S. licensed anthrax vaccine adsorbed were studied. Anti-PA IgG concentrations were measured by ELISA. All 246 vaccinees had low but detectable pre-immunization anti-PA IgG (GMC 1.83 microg/mL). Three doses elicited a GMC of 59.92 microg/mL and a seroconversion rate of 85.3%, four doses elicited a GMC of 157.44 microg/mL and 67.9% and the sixth of 276.95 microg/mL and 45.5%, respectively. The forth dose elicited 100% seroconversion compared to the pre-immunization level. These results should facilitate comparison between different immunization schedules and new vaccines.

Citing Articles

Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.

Green M, LeDuc J, Cohen D, Franz D Lancet Infect Dis. 2018; 19(1):e2-e13.

PMID: 30340981 PMC: 7106434. DOI: 10.1016/S1473-3099(18)30298-6.

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.

Yamamoto B, Shadiack A, Carpenter S, Sanford D, Henning L, Gonzales N Antimicrob Agents Chemother. 2016; 60(10):5796-805.

PMID: 27431219 PMC: 5038297. DOI: 10.1128/AAC.01102-16.

Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.

Bernstein D, Jackson L, Patel S, El Sahly H, Spearman P, Rouphael N Vaccine. 2014; 32(47):6284-93.

PMID: 25239484 PMC: 4250293. DOI: 10.1016/j.vaccine.2014.08.076.

Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Ovsyannikova I, Pankratz V, Vierkant R, Pajewski N, Quinn C, Kaslow R Infect Immun. 2013; 81(7):2584-91.

PMID: 23649091 PMC: 3697592. DOI: 10.1128/IAI.00269-13.

Vaccine protection against Bacillus cereus-mediated respiratory anthrax-like disease in mice.

Oh S, Maier H, Schroeder J, Richter G, Elli D, Musser J Infect Immun. 2013; 81(3):1008-17.

PMID: 23319564 PMC: 3584855. DOI: 10.1128/IAI.01346-12.

References

ERDOS L . [The problem of interval in primary immunization consisting of several vaccinations]. Z Gesamte Hyg. 1974; 20(11):784-8. View

Hoffmaster A, Hill K, Gee J, Marston C, De B, Popovic T . Characterization of Bacillus cereus isolates associated with fatal pneumonias: strains are closely related to Bacillus anthracis and harbor B. anthracis virulence genes. J Clin Microbiol. 2006; 44(9):3352-60. PMC: 1594744. DOI: 10.1128/JCM.00561-06. View

Barr M, GLENNY A, Randall K . Diphtheria immunization in young babies; a study of some factors involved. Lancet. 1950; 1(6593):6-10. DOI: 10.1016/s0140-6736(50)90213-3. View

Brachman P, Kaufman A, DALLDORF F . Industrial inhalation Anthrax. Bacteriol Rev. 1966; 30(3):646-59. PMC: 378258. DOI: 10.1128/br.30.3.646-659.1966. View

Blanchard J, Haywood Y, Stein B, Tanielian T, Stoto M, Lurie N . In their own words: lessons learned from those exposed to anthrax. Am J Public Health. 2005; 95(3):489-95. PMC: 1449207. DOI: 10.2105/AJPH.2004.038349. View

Turnbull P, Leppla S, Broster M, Quinn C, Melling J . Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol. 1988; 177(5):293-303. DOI: 10.1007/BF00189414. View

Brossier F, Levy M, Landier A, Lafaye P, Mock M . Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun. 2004; 72(11):6313-7. PMC: 523002. DOI: 10.1128/IAI.72.11.6313-6317.2004. View

Friedlander A, Pittman P, Parker G . Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA. 1999; 282(22):2104-6. DOI: 10.1001/jama.282.22.2104. View

Quinn C, Dull P, Semenova V, Li H, Crotty S, Taylor T . Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis. 2004; 190(7):1228-36. DOI: 10.1086/423937. View

10.

Lim N, Kim J, Oh M, Lee S, Kim S, Kim K . An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun. 2005; 73(10):6547-51. PMC: 1230968. DOI: 10.1128/IAI.73.10.6547-6551.2005. View

11.

Hanson J, Taft S, Weiss A . Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol. 2006; 13(2):208-13. PMC: 1391949. DOI: 10.1128/CVI.13.2.208-213.2006. View

12.

Avashia S, Riggins W, Lindley C, Hoffmaster A, Drumgoole R, Nekomoto T . Fatal pneumonia among metalworkers due to inhalation exposure to Bacillus cereus Containing Bacillus anthracis toxin genes. Clin Infect Dis. 2007; 44(3):414-6. DOI: 10.1086/510429. View

13.

Pittman P, Norris S, Barrera Oro J, Bedwell D, Cannon T, McKee Jr K . Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006; 24(17):3654-60. DOI: 10.1016/j.vaccine.2006.01.054. View

14.

Bower W, Schiffer J, Atmar R, Keitel W, Friedlander A, Liu L . Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019; 68(4):1-14. PMC: 6918956. DOI: 10.15585/mmwr.rr6804a1. View

15.

Lininger L, Cullum M, Lyles M, Bienek D . The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine. Vaccine. 2006; 25(9):1619-25. DOI: 10.1016/j.vaccine.2006.11.005. View

16.

Price B, Liner A, Park S, Leppla S, Mateczun A, Galloway D . Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun. 2001; 69(7):4509-15. PMC: 98526. DOI: 10.1128/IAI.69.7.4509-4515.2001. View

17.

Ashkenazi S, Passwell J, Harlev E, Miron D, Dagan R, Farzan N . Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis. 1999; 179(6):1565-8. DOI: 10.1086/314759. View

18.

Rubertone M, Brundage J . The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002; 92(12):1900-4. PMC: 1447349. DOI: 10.2105/ajph.92.12.1900. View

19.

Myers M, Beckman C, Vosdingh R, Hankins W . Primary immunization with tetanus and diphtheria toxoids. Reaction rates and immunogenicity in older children and adults. JAMA. 1982; 248(19):2478-80. View

20.

Pittman P, Pifat D, Coonan K, Gibbs P, Little S, Pace-Templeton J . Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine. 2002; 20(9-10):1412-20. DOI: 10.1016/s0264-410x(01)00462-5. View